- Home
- CC vs NNNN Comparison
CC vs NNNN Comparison
Compare CC & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CC
- NNNN
- Stock Information
- Founded
- CC 2014
- NNNN 2021
- Country
- CC United States
- NNNN Germany
- Employees
- CC N/A
- NNNN N/A
- Industry
- CC Major Chemicals
- NNNN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- CC Industrials
- NNNN Health Care
- Exchange
- CC Nasdaq
- NNNN Nasdaq
- Market Cap
- CC 2.3B
- NNNN 2.2B
- IPO Year
- CC N/A
- NNNN 2025
- Fundamental
- Price
- CC $12.57
- NNNN $20.91
- Analyst Decision
- CC Buy
- NNNN
- Analyst Count
- CC 8
- NNNN 0
- Target Price
- CC $17.50
- NNNN N/A
- AVG Volume (30 Days)
- CC 3.3M
- NNNN 35.0K
- Earning Date
- CC 11-06-2025
- NNNN 04-28-2026
- Dividend Yield
- CC 2.81%
- NNNN N/A
- EPS Growth
- CC N/A
- NNNN N/A
- EPS
- CC N/A
- NNNN 0.06
- Revenue
- CC $5,837,000,000.00
- NNNN $8,185,146.00
- Revenue This Year
- CC $4.77
- NNNN N/A
- Revenue Next Year
- CC $4.39
- NNNN N/A
- P/E Ratio
- CC N/A
- NNNN $417.85
- Revenue Growth
- CC 0.03
- NNNN 21.95
- 52 Week Low
- CC $9.13
- NNNN $5.18
- 52 Week High
- CC $22.38
- NNNN $55.65
- Technical
- Relative Strength Index (RSI)
- CC 51.14
- NNNN 44.83
- Support Level
- CC $10.44
- NNNN $20.00
- Resistance Level
- CC $13.04
- NNNN $29.38
- Average True Range (ATR)
- CC 0.72
- NNNN 3.65
- MACD
- CC 0.14
- NNNN 0.45
- Stochastic Oscillator
- CC 77.68
- NNNN 41.87
About CC Chemours Company (The)
The Chemours Co is a provider of chemicals. It delivers customized solutions with a wide range of industrial and specialty chemicals products for various markets including coatings, plastics, refrigeration, air conditioning, etc. The company's operating segments include Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. It generates maximum revenue from the Titanium Technologies segment. The Titanium Technologies segment is a producer of TiO2 pigment, a premium white pigment used to deliver whiteness, brightness, opacity, durability, efficiency, and protection across a variety of applications. Geographically, the company derives a majority of its revenue from North America.
About NNNN Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.